Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Rhea-AI Summary
Nutriband (NASDAQ:NTRB)/b) announced that CEO and Co-Founder will present in the CEO Spotlight at the 2026 Georgia Life Sciences Summit on August 26, 2026. The Summit, held August 25–26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, convenes leaders from biotechnology, medical technology, research, manufacturing, and investment.
Positive
- None.
Negative
- None.
News Market Reaction – NTRB
In the Aug 13 session, NTRB gained 3.74%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Conference product showcase | Neutral | +0.3% | Showcased AI wellness products and announced planned June launches at ECRM. |
| Apr 22 | CEO podcast appearance | Neutral | -0.2% | Discussed fentanyl crisis, AVERSA technology, and medication abuse-deterrence opportunity on podcast. |
| Mar 30 | Product naming update | Neutral | +2.0% | Selected a commercial brand name candidate and planned FDA and international submissions. |
| Mar 18 | Costa Rica approval | Positive | +0.5% | Ministry of Health approved kinesiology tapes, AVERSA products, and mosquito repellent patches. |
| Feb 17 | Distribution agreement | Positive | +4.0% | Signed exclusive Costa Rica distribution agreement covering AVERSA fentanyl and sports tape products. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational announcements were followed by positive 24-hour reactions, while neutral promotional or media items showed mixed direction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26th as part of the CEO spotlight event.
The Georgia Life Sciences Summit brings together leaders from across biotechnology, medical technology, research, manufacturing, and investment to showcase Georgia’s emergence as a national leader in life sciences innovation.
The Summit takes place on Aug 25-26 at the Sandy Springs Performing Arts Centre located at 1 Galambos Way, Sandy Springs, Georgia.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
